European Commission Approves TEPKINLY + R2 for Relapsed or Refractory Follicular Lymphoma in the Second-Line Setting – Genmab
Genmab A/S announced that the European Commission (EC) granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adult… read more.
